<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CD117 is a transmembrane protein receptor encoded by the c-kit proto-oncogene </plain></SENT>
<SENT sid="1" pm="."><plain>The CD117 ligand is stem cell factor, an important hematopoietic regulator </plain></SENT>
<SENT sid="2" pm="."><plain>CD117 is present on approximately 4% of <z:mpath ids='MPATH_458'>normal</z:mpath> bone marrow mononuclear cells and in <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> in myeloid <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e>, but rarely in <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) </plain></SENT>
<SENT sid="3" pm="."><plain>Initially viewed as a primitive myeloid marker, CD117 has been identified in <z:hpo ids='HP_0000001'>all</z:hpo> FAB subtypes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and may predict poor outcome </plain></SENT>
<SENT sid="4" pm="."><plain>CD34, a primitive stem cell marker, may also predict poor outcome </plain></SENT>
<SENT sid="5" pm="."><plain>The aim of this study was to examine the relationship between CD117 and CD34 expression on leukemic blasts and to determine whether CD117 is related to lymphoid-associated antigen (LAA) expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Consecutive bone marrow samples were studied from cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (30 cases), <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (4 cases), <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>-BC) (6 cases), and ALL (5 cases) </plain></SENT>
<SENT sid="7" pm="."><plain>Cases were diagnosed according to FAB criteria and included M0 (3 cases), M1 (2 cases), M2 (13 cases), M3 (1 case), M4 (6 cases), M5 (3 cases), M6 (1 case), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> NOS (1 case), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> (3 cases), and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> (1 case) </plain></SENT>
<SENT sid="8" pm="."><plain>CD117 and CD34 were analyzed by multiparameter flow cytometry </plain></SENT>
<SENT sid="9" pm="."><plain>Blasts in 10 de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> samples were CD117+/CD34+ in 4 cases, CD117+/CD34-in 3 cases, CD117-/CD34+ in 1 case, and CD117-/ CD34- in 2 cases </plain></SENT>
<SENT sid="10" pm="."><plain>Blasts in 20 cases of relapsed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> were CD117+/ CD34+ in 13 cases, CD117+/CD34- in 6 cases, and CD117-/CD34+ in 1 case </plain></SENT>
<SENT sid="11" pm="."><plain>Blasts in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were CD117+/CD34+ in 3 cases, CD117-/ CD34+ in 1 case </plain></SENT>
<SENT sid="12" pm="."><plain>Blasts in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>-BC were CD117+/CD34+ in 4 cases, CD117-/CD34+ in 2 cases </plain></SENT>
<SENT sid="13" pm="."><plain>Blasts in ALL were CD117+/CD34+ in 1 case, CD117-/CD34+ in 1 case, CD117-/CD34- in 3 cases </plain></SENT>
<SENT sid="14" pm="."><plain>Of 26 cases of CD117+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, CD4 was expressed in 15 (58%) cases, CD7 in 7 (27%) cases, and CD2 in 2 (8%) cases </plain></SENT>
<SENT sid="15" pm="."><plain>CD117/CD34 expression did not correlate with FAB subtype of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="16" pm="."><plain>CD117 is borne on most leukemic blasts of myeloid origin (in this study, 87% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 80% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>-myeloid BC, and 75% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and does not exclude expression of LAA </plain></SENT>
<SENT sid="17" pm="."><plain>Although CD117 is a receptor for stem cell factor, its expression does not appear to correlate with CD34 positivity </plain></SENT>
</text></document>